← Leaderboards
Thomas P Burris
Lsu Pennington Biomedical Research Ctr
$18,547,077
Attributed
$22,366,515
Total exposure
15
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,366,515 · 15
By mechanism
R01$13,298,160 · 4
RF1$5,946,615 · 2
R21$1,072,893 · 4
T32$762,110 · 2
R24$583,224 · 1
R33$380,434 · 1
Top collaborators
- John K. Walker10 shared
- Terrance M Egan2 shared
- Mark M Voigt2 shared
- Bahaa Elgendy1 shared
Others in their field
Top investigators on “Ligands”
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,009,297
- Keith W Miller · Massachusetts General Hospital$35,506,092
- Ian A Wilson · Scripps Research Institute, The$35,392,112
- Bryan L Roth · Univ Of North Carolina Chapel Hill$32,442,555
- Edward Franklin Plow · Cleveland Clinic Foundation$32,215,714
- Helen M Berman · Rutgers University New Brunswick$32,076,400
Research focus
LigandsReceptorPropertyAgonistNuclear ReceptorsOrphanPhysiologicalHuman DiseaseCircadian RhythmsDrug KineticsIn VivoRegulationMetabolismPlayInnovationMemberAnimalsPhysiological ProcessesAffinityCellsPharmaceutical PreparationsBasePharmacologyMental Depression
Grant awards (41)
University of Florida Genetics Training Program$426,360
T32 · FY2025 · GM · contact PI
Screening for Nuclear Receptor TLX ligands$380,434
R33 · FY2025 · NS · contact PI
Screening for Nuclear Receptor TLX ligands$323,079
R61 · FY2024 · NS · contact PI
Exercise Mimetics for Dementia and Alzheimer's Disease$2,262,938
RF1 · FY2023 · AG · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$502,895
R01 · FY2020 · MH · contact PI
Targeting REV-ERB to treat Alzheimer's disease$1,987,705
RF1 · FY2019 · AG · contact PI
Targeting REV-ERB to treat Alzheimer's disease$1,695,972
RF1 · FY2019 · AG · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$470,731
R01 · FY2019 · MH · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$402,527
R01 · FY2019 · MH · contact PI
ERRgamma Agonists to Treat Muscular Dystrophy$536,587
R01 · FY2018 · AR · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$536,393
R01 · FY2018 · MH · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$59,600
R01 · FY2018 · MH · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$595,993
R01 · FY2017 · MH · contact PI
ERRgamma Agonists to Treat Muscular Dystrophy$580,666
R01 · FY2017 · AR · contact PI
Pharmacological Sciences Training Grant$168,886
T32 · FY2017 · GM · contact PI
Development of RORalpha and RORgamma Ligands for Treatment of Behavioral Disorders$662,214
R01 · FY2016 · MH · contact PI
REV-ERB ligands for treatment of anxiety disorders$627,837
R01 · FY2016 · MH · contact PI
ERRgamma Agonists to Treat Muscular Dystrophy$580,666
R01 · FY2016 · AR · contact PI
Pharmacological Sciences Training Grant$166,864
T32 · FY2016 · GM · contact PI
REV-ERB ligands for treatment of anxiety disorders$623,103
R01 · FY2015 · MH · contact PI
REV-ERB ligands for treatment of anxiety disorders$618,458
R01 · FY2014 · MH · contact PI
Development of ROR ligands for treatment of circadian rhythm disorders$567,190
R01 · FY2014 · MH · contact PI
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands$202,466
R21 · FY2014 · AA · contact PI
Development of ROR ligands for treatment of circadian rhythm disorders$36,798
R01 · FY2014 · MH · contact PI
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands$15,239
R21 · FY2014 · AA · contact PI
REV-ERB ligands for treatment of anxiety disorders$834,463
R01 · FY2013 · MH · contact PI
Development of ROR ligands for treatment of circadian rhythm disorders$714,610
R01 · FY2013 · MH · contact PI
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands$271,688
R21 · FY2013 · AA · contact PI
REV-ERB ligands for treatment of anxiety disorders$883,539
R01 · FY2012 · MH · contact PI
Development of ROR ligands for treatment of circadian rhythm disorders$744,383
R01 · FY2012 · MH · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$388,120
R01 · FY2012 · DK · contact PI
Development of ROR ligands for treatment of circadian rhythm disorders$814,847
R01 · FY2011 · MH · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$388,120
R01 · FY2011 · DK · contact PI
Development of ROR ligands for treatment of metabolic diseases$583,224
R24 · FY2010 · DK · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$385,110
R01 · FY2010 · DK · contact PI
Development of an HTS assay to identify FXR antagonists$194,500
R21 · FY2010 · NS · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$389,000
R01 · FY2009 · DK · contact PI
Development of a High Throughput Screening Assay for RORgamma$194,500
R21 · FY2009 · NS · contact PI
Development and Validation of a REV-ERBalpha HTS Assay$194,500
R21 · FY2009 · NS · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$246,953
R01 · FY2008 · DK · contact PI
Regulation of REV-ERBalpha and REV-ERBbeta function of HEME$107,357
R01 · FY2008 · DK · contact PI